Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | THRB | P10828 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | NOS2 | P35228 | 2/20 | 0.57 |
| ▸ | FADS1 | O60427 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.48 |
| ▸ | GCK | P35557 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11134942 | 0.88 | POLB (0.72) | RECQLPOLBTHRBTDP1L3MBTL1 | |
| SCHEMBL11689255 | 0.87 | NOS2 (0.63) | RECQLPOLBTHRBTDP1L3MBTL1 | |
| SCHEMBL10705234 | 0.86 | CDK1 (0.57) | RECQLPOLBTHRBTDP1L3MBTL1 | |
| SCHEMBL8771439 | 0.84 | ALDH1A1 (0.67) | RECQLPOLBTHRBTDP1L3MBTL1 | |
| SCHEMBL13634359 | 0.83 | POLB (0.49) | RECQLPOLBTHRBTDP1L3MBTL1 | |
| SCHEMBL8771566 | 0.82 | ALDH1A1 (0.56) | RECQLPOLBTHRBTDP1L3MBTL1 | |
| SCHEMBL7104333 | 0.81 | L3MBTL1 (0.48) | RECQLPOLBTHRBTDP1L3MBTL1 | |
| SCHEMBL10789586 | 0.81 | POLB (1.00) | RECQLPOLBTHRBTDP1L3MBTL1 | |
| SCHEMBL1095186 | 0.80 | ALDH1A1 (0.70) | RECQLTDP1L3MBTL1NOS2FADS1 | |
| SCHEMBL7096117 | 0.80 | ALDH1A1 (0.65) | RECQLPOLBTHRBTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010018405-A1 | Process for preparation of pyrimidinone derivatives | WALTER HARALD (CH) | 2001-08-30 | — | — | US | disclosed |
| EP-1087939-A1 | PROCESS FOR PREPARATION OF PYRIMIDINONE DERIVATIVES | Syngenta Participations AG (CH) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999067202-A1 | PROCESS FOR PREPARATION OF PYRIMIDINONE DERIVATIVES | SYNGENTA PARTICIPATIONS AG . (CH) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018405-A1 | Process for preparation of pyrimidinone derivatives | CBR1, CBR3, CYP4F8 | RECQL 2990/4885POLB 1783/4885THRB 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.